CoChat

A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer

Open access
Gold, Kathryn A., Lee, J. Jack, Harun, Nusrat, Tang, Ximing, Price, Justina, Kawedia, Jitesh D., Tran, Hai T., Erasmus, Jeremy J., Blumenschein, George R., William, William N., Wistuba, Ignacio I., Johnson, Faye M. · 2014 · The Oncologist
Cited by 46

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background.: EGFR and Src are frequently activated in non-small cell lung cancer (NSCLC). In preclinical models, combining EGFR and Src inhibition has additive synergistic effects. We conducted a phase I/II trial of the combination of Src inhibitor dasatinib with EGFR inhibitor erlotinib to determine the maximum tolerated dose (MTD), pharmacokinetic drug interactions, biomarkers, and efficacy in NSCLC. Methods.: The phase I 3+3 dose-escalation study enrolled patients with solid tumors to determine the MTD. The phase II trial enrolled patients with advanced NSCLC who had undergone no previous treatments to determine progression-free survival (PFS) and response. Pharmacokinetic and tissue biomarker analyses were performed. Results.: MTD was 150 mg of erlotinib and 70 mg of dasatinib daily based on 12 patients treated in the phase I portion. No responses were observed in phase I. The 35 NSCLC patients treated in phase II had an overall disease control rate of 59% at 6 weeks. Five patients (15%) had partial responses; all had activating EGFR mutations. Median PFS was 3.3 months. Epithelial-mesenchymal transition markers did not correlate with outcomes. Conclusion.: The combination of erlotinib and dasatinib is safe and feasible in NSCLC. The results of this study do not support use of this combination in molecularly unselected NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2014-0228

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 46

Metadata

Authors
Gold, K. A., Lee, J. J., Harun, N., Tang, X., Price, J., Kawedia, J. D., Tran, H. T., Erasmus, J. J., Blumenschein, G. R., William, W. N., Wistuba, I. I., & Johnson, F. M.
Venue
The Oncologist
Published
2014-08-28
Volume
19
Issue
10
Pages
1040-1041
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2171101164
Cited by
46
References
3
FWCI
3.63
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1634/theoncologist.2014-0228
The paper
Gold, K. A., Lee, J. J., Harun, N., Tang, X., Price, J., Kawedia, J. D., Tran, H. T., Erasmus, J. J., Blumenschein, G. R., William, W. N., Wistuba, I. I., & Johnson, F. M. (2014). A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer. The Oncologist. https://doi.org/10.1634/theoncologist.2014-0228

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.